We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01890837
Recruitment Status : Completed
First Posted : July 2, 2013
Last Update Posted : June 13, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

June 27, 2013
July 2, 2013
June 13, 2016
August 2013
March 2015   (Final data collection date for primary outcome measure)
  • Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS [ Time Frame: 14 days ]
  • Sensation threshold for pain in response to distention of the rectum [ Time Frame: 14 days ]
Same as current
Complete list of historical versions of study NCT01890837 on ClinicalTrials.gov Archive Site
  • Rectal compliance at half-maximum pressure (Pr1/2) [ Time Frame: 14 days ]
  • Rectal sensation thresholds (gas, urgency to defecate, first sensation) [ Time Frame: 14 days ]
  • Rectal sensation ratings (pain, gas) in response to 32 mmHg distension of the rectum [ Time Frame: 14 days ]
  • Rectal tone response to feeding 1,000 kcal meal [ Time Frame: 14 days ]
  • Stool frequency [ Time Frame: 21 days ]
  • Stool consistency as measured by the Bristol stool scale [ Time Frame: 21 days ]
  • Daily average severity of abdominal pain on 100mm VAS [ Time Frame: 21 days ]
  • Worst severity of abdominal pain each day measured on 100mm VAS scale [ Time Frame: 21 days ]
  • Daily average severity of bloating on 100mm VAS scale [ Time Frame: 21 days ]
  • IBS-QOL (Quality of Life) score [ Time Frame: 14 days ]
  • Ease of bowel movements [ Time Frame: 21 days ]
  • Completeness of evacuation [ Time Frame: 21 days ]
  • Rectal compliance at half-maximum pressure (Pr1/2) [ Time Frame: 14 days ]
  • Rectal sensation thresholds (gas, urgency to defecate) [ Time Frame: 14 days ]
  • Rectal pain sensation rating [ Time Frame: 14 days ]
  • Rectal tone response to feeding 1,000 kcal meal [ Time Frame: 14 days ]
  • Stool frequency [ Time Frame: 21 days ]
  • Stool consistency as measured by the Bristol stool scale [ Time Frame: 21 days ]
  • Daily average severity of pain on 100mm Visual Analog Scale (VAS) [ Time Frame: 21 days ]
  • Worst severity of pain each day measured on 100mm VAS scale [ Time Frame: 21 days ]
  • Daily average severity of bloating on 100mm VAS scale [ Time Frame: 21 days ]
  • IBS-QOL (Quality of Life) score [ Time Frame: 14 days ]
Not Provided
Not Provided
 
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome
The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Irritable Bowel Syndrome
  • Digestive System Diseases
  • Gastrointestinal Diseases
  • Intestinal Diseases
  • Abdominal Pain
  • Drug: Daikenchuto (TU-100)
    Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
  • Drug: Placebo
    Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
  • Experimental: Daikenchuto (TU-100) 15g/day
    Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
    Intervention: Drug: Daikenchuto (TU-100)
  • Placebo Comparator: Placebo
    Placebo TID
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
March 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Meet Rome III criteria for IBS.
  2. Willing and able to provide written informed consent.
  3. If a female of childbearing potential, must be using an acceptable form of contraception during the study and for 30 days after the last dose. Acceptable methods include surgical sterilization, hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing), condoms used with a spermicide, an IUD [Intrauterine device] or abstinence.

    Females are not considered to be of childbearing potential if they are postmenopausal for at least 2 years or have been surgically sterilized.

  4. Aged 18 to 65 years, inclusive.
  5. Have a body mass index (BMI) between 18 and 40 kg/m2, inclusive.
  6. Have a negative urine drug screening at Visit 1.
  7. Have normal or not clinically significant laboratory results as reviewed by the study physicians.
  8. Have a normal rectal examination result on file within the past 2 years or performed at Visit 1 in order to exclude the possibility of an evacuation disorder (examination must exclude findings suggestive of an evacuation disorder such as high sphincter tone at rest, failure of perineal descent and spasm, tenderness or paradoxical contraction of the puborectalis muscles).
  9. Agree to avoid alcohol during the entire study to avoid corrupting the data from the rectal barostat tests.

Exclusion Criteria:

  1. Have a structural or metabolic diseases or conditions that affect the GI system.
  2. Be taking any medication that in the opinion of the principal investigator has a potential to alter GI transit (this includes but is not limited to osmotic or stimulant laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, gabapentin, pregabalin, narcotics, anticholinergics, antidepressants [including selective norepinephrine reuptake inhibitors], antipsychotics, opiates, GABAergic agents and benzodiazepines).

    Note: Tricyclic antidepressants are permissible at doses equal to or less than 25 mg daily; selective serotonin reuptake inhibitor antidepressants are permissible at low, stable doses. Analgesics such as Tylenol, ibuprofen, naproxen and aspirin are not permissible during Visits 2 and 3 to avoid corrupting data from the rectal barostat tests. All medications will be reviewed by the principal investigator on a case by case basis.

    Rescue medications: Rescue medications will be reviewed and approved as necessary for exacerbation of constipation or diarrhea since the study medication treatment period is about 14 days total. The patient will contact the study staff to request review and approval of the use of a rescue medication by the principal investigator. The use of the rescue medication will be documented by the patient in the bowel pattern, bloating and pain diary. Rescue medications are not allowed within 7 days of the rectal sensation studies to ensure data integrity.

  3. Have clinical evidence, including but not limited to, of a clinically significant abnormal physical examination or laboratory value or of a past event documented in the past medical record, or current clinically significant abnormal physical examination or laboratory value that could indicate significant cardiovascular, respiratory, renal, hepatic, GI, hematological, neurological, psychiatric or other diseases that interfere with the objectives of the study. If a laboratory test value falls outside of the reference range and is considered clinically significant, it may be repeated once at the discretion of the principal investigator. If the laboratory test result remains abnormal and clinically significant, the patient will be discontinued from the study and referred to a primary care physician for evaluation.
  4. Be a known substance abuser or be considered to be an alcoholic not in remission.
  5. Have participated in another clinical study in the past 30 days.
  6. Have a history of allergic reactions to egg, ginseng, ginger or Sichuan pepper.
  7. Be clinically lactose intolerant.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01890837
TU100CPT5
No
Not Provided
Not Provided
Tsumura USA
Tsumura USA
Cato Research
Principal Investigator: Michael Camilleri, MD Mayo Clinic
Tsumura USA
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP